T11-036 Tohoku University’s Invention Anti-cancer drug with HDAC and PI3K inhibitory activity low molecular weight compound with anti-cancer activity for nano-molarity

First Page		Document Content
Date: 2012-09-27 22:51:13 Prodrugs Drug discovery Phosphoinositide 3-kinase inhibitor Histone deacetylase Romidepsin Phosphoinositide 3-kinase LY294002 Wortmannin Medicine Pharmacology Depsipeptides		T11-036 Tohoku University’s Invention Anti-cancer drug with HDAC and PI3K inhibitory activity low molecular weight compound with anti-cancer activity for nano-molarity Add to Reading List Source URL: www.t-technoarch.co.jp Download Document from Source Website File Size: 175,62 KB Share Document on Facebook

	Media Release Basel (Switzerland), May 28, 2015 PIQUR announces positive Phase 1 study results and the start of Phase 2 of PQR309 Study confirms that PQR309 is well tolerated and shows promising signs of DocID: 1oXMN - View Document
	T11-036 Tohoku University’s Invention Anti-cancer drug with HDAC and PI3K inhibitory activity low molecular weight compound with anti-cancer activity for nano-molarity DocID: 11Qnc - View Document
	Citation: Cell Death and Disease[removed], e106; doi:[removed]cddis[removed] & 2010 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis Differential effects of the phosphatidylinositol DocID: ZWQi - View Document
	FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway DocID: Zu2j - View Document
	Store at -20ºC Phospho-Akt (Ser473) (193H12) Rabbit mAb #4058 DocID: S1nY - View Document